Amisulpride, a dopamine D2/D3-antagonist, prevents chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic cisplatin or anthracycline-cyclophosphamide regimens: A randomised, double-blind, placebo-controlled, dose-ranging trial

被引：0

作者：

Herrstedt, J. ^{[1
]}

Summers, Y. ^{[2
]}

Jordan, K. ^{[3
]}

Von Pawel, J. ^{[4
]}

Jakobsen, A. H. ^{[5
]}

Ewertz, M. ^{[1
]}

Chan, S. ^{[6
]}

Naik, J. ^{[7
]}

Karthaus, M. ^{[8
]}

Dubey, S. ^{[9
]}

Davis, R. ^{[10
]}

Fox, G. ^{[11
]}

机构：

[1] Odense Univ Hosp, Oncol, DK-5000 Odense, Denmark

[2] Univ S Manchester Hosp, Pulm Oncol Unit, Manchester M20 8LR, Lancs, England

[3] Univ Klinikum Halle Saale, Dept Oncol Haematol, Halle An Der Saale, Germany

[4] Asklepios Fachkliniken, Klin Pneumol, Munich, Germany

[5] Herlev Hosp, Dept Oncol, Copenhagen, Denmark

[6] Univ Nottingham Hosp, Acad Unit Oncol, Nottingham NG7 2UH, England

[7] Mid Yorkshire NHS Trust, Oncol, Wakefield, England

[8] Klinikum Neuperlach, Klin Hamatol Onkol & Palliativmed, Munich, Germany

[9] Derriford Hosp, Dept Oncol, Plymouth PL6 8DH, Devon, England

[10] Wexham Pk Hosp, Canc Clin Trials Off, Slough SL2 4HL, Berks, England

[11] Acacia Pharma Ltd, Clin Dev, Cambridge, England

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30662-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1573

引用

页码：S228 / S229

页数：2

共 44 条

[41] Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (vol 21, pg 242, 2020)
Hashimoto, H.
Abe, M.
Tokuyama, O.
LANCET ONCOLOGY, 2020, 21 (02): : E70 - E70
[42] Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial
Clemmons, Amber B.
Orr, Julianne
Andrick, Benjamin
Gandhi, Arpita
Sportes, Claude
DeRemer, David
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (10) : 2065 - 2071
[43] Study protocol for J-SUPPORT 1604 ( J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy
Hashimoto, Hironobu
Abe, Masakazu
Yanai, Takako
Yamaguchi, Takuhiro
Zenda, Sadamoto
Uchitomi, Yosuke
Fukuda, Haruhiko
Mori, Mikio
Iwasa, Satoru
Yamamoto, Noboru
Ohe, Yuichiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (10) : 950 - 952
[44] Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Kang, Yoon-Koo
Terashima, Masanori
Kim, Young-Woo
Boku, Narikazu
Chung, Hyun Cheol
Chen, Jen-Shi
Ji, Jiafu
Yeh, Ta-Sen
Chen, Li-Tzong
Ryu, Min-Hee
Kim, Jong Gwang
Omori, Takeshi
Rha, Sun Young
Kim, Tae Yong
Ryu, Keun Won
Sakuramoto, Shinichi
Nishida, Yasunori
Fukushima, Norimasa
Yamada, Takanobu
Bai, Li-Yuan
Hirashima, Yoshinori
Hagihara, Shunsuke
Nakada, Takashi
Sasako, Mitsuru
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (08): : 705 - 717

← 1 2 3 4 5 →